Please enter your registered email address to receive password reset messages.
We aim to XXXXXXXXXXX@qq.com I sent an email with a link to reset my password. If you haven't received it, please try checking your spam folder.
Gan & Lee strives to explore frontier breakthroughs in science and disseminate groundbreaking advances while driving research innovation. We are dedicated to offering comprehensive academic support for each of healthcare professionals.
Medical information
Access to medical information about diabetes
Professional guidelines
Download professional guidelines related to diabetes
Conference information
Check diabetes-related academic conferences
Scientific frontiers
Learn about academic developments in diabetes
Focused on the diabetes field for over two decades, Gan & Lee has developed a wide range of anti-diabetic drugs, including long-acting insulin, rapid-acting insulin and premixed insulin. In addition, Gan & Lee is actively developing glucagon-like peptide-1 (GLP-1) receptor agonists, fourth-generation ultra-long-acting once-weekly insulin and dual insulin analogues, aiming to build an anti-diabetic product matrix covering both insulin and innovative hypoglycemic drugs.
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
© 2023 Gan & Lee Pharmaceuticals All Rights Reserved
